Novartis to invest $100m in biopharmaceuticals production in Slovenia

Ljubljana, 12 September - Swiss pharma giant Novartis, of which Slovenian pharma company Lek is a part, plans to invest 300 million US dollars in early technical development capabilities for next-generation biotherapeutics, of which 110 million dollars at one of its Slovenian locations in Mengeš.

Mengeš Drug production machinery at Lek's Mengeš location. Photo: Daniel Novakovič/STA

Mengeš
Drug production machinery at Lek's Mengeš location.
Photo: Daniel Novakovič/STA

The rest of this news item is available to subscribers.
The news item consists of 981 characters (without spaces) or 168 words words.

Buy the news item. Price: 2 tokens; on account: 0 tokens.

sm/bg/ep
© STA, 2022

The STA web pages use cookies to ensure proper functioning of all page features. By using our website, you agree to the use of cookies on all STA web pages.

I want to know more